Company News »

Ophthotech Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014

Business Wire
Share on StockTwits
Published on

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the third quarter ended September 30, 2014, on Tuesday, November 11, 2014. Following the announcement, Ophthotech’s management will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss Ophthotech’s financial results for the third quarter and provide a general business update.

To participate in this conference call, dial 888-359-3624 (USA) or 719-457-2661 (International), and enter passcode 5108855. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Ophthotech website at: A replay will be available approximately two hours following the live call for one week. The replay number will be 888-203-1112 (USA) or 719-457-0820 (International), passcode 5108855. A replay of the audio webcast will be accessible at:

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech’s most advanced product candidate, Fovista(R) anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF drugs that represent the current standard of care for the treatment of wet AMD. Ophthotech’s second product candidate, ZimuraTM, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy (a form of dry AMD) and in combination with Fovista(R) and anti-VEGF therapy for wet AMD. For more information, please visit

Forward-Looking Statements

Any statements in this press release about Ophthotech’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech’s views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.


Share on StockTwits